Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: Relation to disease progression

Leukemia Research

Volumn 22, Issue 9, 1998, Pages 767-777

  Davis, R E ^a,b   Greenberg, P L ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Bcl 2; Immunostaining; Marrow; Myelodysplastic syndromes

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MYELODYSPLASTIC SYNDROME; ONCOGENE; PRIORITY JOURNAL; STEM CELL;

ACUTE DISEASE; BIOPSY; DISEASE PROGRESSION; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS;

EID: 0032171391     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00051-4     Document Type: Article

References (61)

1. [1] Davis RE, Greenberg PL. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: immunostaining of bone marrow biopsies. Blood 1994;84 Suppl 1:314a.
2. [2] Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079.
3. [3] Bennett J, Catovsky D, Daniel M, Flandrin G, Gallon D, Gralnick H, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189.
4. [4] Koeffler H. Myelodysplastic syndromes (preleukemia). Semin Haematol 1986;23:284.
5. [5] Wyllie AH, Kerr JFR, Currie AH. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251.
6. [6] Wyllie AH. Cell death. Int Rev Cytol 1987;17:755.
7. [7] Walker NI, Harmon BV, Gobe GC, Kerr JFR. Patterns of cell death. Meth Achiev Exp Pathol 1988;13:18.
8. [8] Greenberg P. Programmed cell death (apoptosis) as a mechanism for regulating haematopoietic cell population size. Focus on Growth Factors 1992;3:1.
9. [9] Vaux D. Toward understanding of the molecular mechanism of physiological cell death. Proc Natl Acad Sci USA 1993;90:786.
10. [10] Yoshida Y, Anzai N, Kawabata H. Apoptosis in myelodysplasia: a paradox or paradigm. Leukemia Res 1995;19:887.
11. [11] Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Lowe JBM, Khan Z, Chaney C, Showel J, Gregory S, Preisler H. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86:268.
12. [12] Raza A, Mundle S, Iftikhar A, Gregory S, Marcus B, Khan Z, Alvi S, Shetty V, Damerson S, Wright V, Adler S, Loew JM, Shott S, Ali SN, Preisler H. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 1995;48:143.
13. [13] Mundle S, Iftikhar A, Shetty V, Dameron S, Wright-Quinones V, Marcus B, Lowe J, Gregory S, Raza A. Novel in situ double labeling for simultaneous detection of proliferation and apoptosis. J Histochem Cytochem 1994;42:1533.
14. [14] Rajapaksa R, Ginzton N, Rott L, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996;88:4275.
15. [15] Hockenbery D, Zutter M, Hickey W, Nahm M. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961.
16. [16] Gaulard P, d'Agay M-F, Peuchmaur M, Brousse N, Gisselbrecht C, Solal-Celigny P, Diebold J, Mason DY. Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 1992;140:1089.
17. [17] Schena M, Larsson L-G, Gottardi D, Gaidano G. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992;79:2981.
18. [18] Vaux D, Cory S, Adams J. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440.
19. [19] Vaux D, Weissman I. Neither macromolecular synthesis nor myc is required for cell death via the mechanism that can be controlled by bcl-2. Mol Cell Biol 1993;13:7000.
20. [20] McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, Korsmeyer SJ. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;57:79.
21. [21] McDonnell T, Korsmeyer S. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 1991;349:254.
22. [22] Delia D, Aiello A, Soligo D, Fontanella E. Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 1992;79:1291.
23. [23] Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 1995;9:1191.
24. [24] Campos L, Rouault J-P, Sabiolo O, Oriol P, Roubi N, Vasselan C, Archimbaud E. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81:3091.
25. [25] Bradbury D, Zhu Y-M, Hunter A, Russell N. Acute myeloblastic leukemia cells with autonomous growth express high levels of bcl-2 protein which is regulated by autocrine growth factors. Blood 1993;82 Suppl 1:124a.
26. [26] Campos L, Sabido O, Rouault J-P, Guyotat D. Effects of bcl-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 1994;84:595.
27. [27] Nunez G, London L, Korsmeyer S. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cells lines. J Immunol 1990;144:3602.
28. [28] Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334.
29. [29] Han JH, Gileadi C, Rajapaksa R, Kosek J, Greenberg PL. Modulation of apoptosis in human myeloid leukemic cells by granulocyte-macrophage colony-stimulating factor. Exp Hematol 1995;23:265.
30. [30] Koury M. Programmed cell death (apoptosis) in hematopoiesis. Exp Hematol 1992;20:391.
31. [31] Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990;248:378.
32. [32] Rodriguez-Tarduchy, G., Collins, M., Lopez-Rivas, A. Regulation of apoptosis in interleukin-3 dependent hemopoietic cells by interleukin-3 and calcium ionophores. EMBO J 1990;9
33. [33] Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 1990;343:76.
34. [34] Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 1993;82:15.
35. [35] Greenberg P, Taylor K, Larson R, Koeffler P, Negrin R., Saba, H, Ganser A, Jakubowski A, Lamborn K, Brown S. Phase III randomized multicenter trial of G-CSF versus observation for myelodysplastic syndromes (MDS). Blood 1993;82 Suppl 1:196a.
36. [36] Lambertenghi-Deliliers G, Annaloro C, Oriani A, Soligo D, Pozzoli E, Polli EE. Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes. Ann Hematol 1993;66:85.
37. [37] Utz GL, Cualing HD. Bcl-2 protein expression in bone marrow biopsy correlates with phase in CML. Mod Pathol 1994;7:122A.
38. [38] Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with bcl-2 protein expression in acute myeloid leukemia. Blood 1997;89:243.
39. [39] Maung ZT, MacLean FR, Reid MM, Pearson ADJ, Proctor SJ, Hamilton PJ, Hall AG. The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Br J Haematol 1994;88:105.
40. [40] Rinaudo MS, Su K, Falk LA, Halder S, Mufson RA. Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells. Blood 1995;86:80.
41. [41] Hulette BC, Banavali SD, Finke DP, Gopal V, Preisler HD. Proto-oncogene expression in subpopulations of cells from leukemia patients. Cytometry 1992;13:653.
42. [42] San Miguel JF, Martinez A, Macedo A, Vidriales MB, López-Berges C, Gonzalez M, Caballero D, Garcia-Marcos MA, Ramos F, Fernández-Calvo J, Calmuntia MJ, Diaz-Mediavilla J, Orfao A. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997;90:2465.
43. [43] Del Canizo MC, Galende J, Mota A, Orfao A, Martinez A, Almeida J, San Miguel JF. In leukemic hematopoiesis CD34 antigen does not have the same significance as it does in normal hematopoiesis. Leukemia Res 1997;21:651.
44. [44] Bernasconi P, Alessandrino EP, Boni M, Bonfichi M, Morra E, Lazzarino M, Campagnoli C, Astori C. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. Am J Hematol 1994;46:270.
45. [45] Jacobs RH, Cornbleet MA, Vardiman JW, Larson RA, LeBeau MM, Rowley JD. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 1986;67:1765.
46. [46] Jenkins R, Le Beau M, Kraker W, Borell T. Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens. Blood 1992;79:3307.
47. [47] van Lom K, Hagemeijer A, Vandekerckhove F, Smit EME, Löwenberg B. Cytogenetic clonality analysis: typical patterns in myelodysplastic syndrome and acute myeloid leukemia. Br J Haematol 1996;93:594.
48. [48] Van Der Lily N, Poddighe P, Wessels J, Hopman A, Geurts van Kessel A, De Witte T. Clonal analysis of progenitor cells by interphase cytogenetics in patients with acute myeloid leukemia and myelodysplasia. Leukemia 1995;9:1167.
49. [49] Mecucci C, Van den Berghe H. Myelodysplastic syndromes: cytogenetics. Hematol Oncol Clin North Am 1992;6:523.
50. [50] Tricot G, DeWolf-Peeters C, Hendrickx B, Verwilghen RL. Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br J Haematol 1984;57:423.
51. [51] Tricot G, DeWolf-Peeters C, Vlietinck R, Verwilghen RL. Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 1984;58:217.
52. [52] Anastasi J. Molecular cytogenetics and the myelodysplastic syndromes. Leuk Res 1996;20:559.
53. [53] Larsen CJ. The bcl-2 gene: prototype of a gene family that controls programmed cell death (apoptosis). Ann Genet 1994;37:121.
54. [54] Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597.
55. [55] Oltvai Z, Milliman C, Korsmeyer S. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programed cell death. Cell 1993;74:609.
56. [56] Miyashita T, Reed J. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293.
57. [57] Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of meyloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345.
58. [58] Gottlieb E, Haffner R, von Ruden T, Wagner EF, Oren M. Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J 1994;13:1368.
59. [59] Chiou S, Rao L, White E. Bcl-2 blocks p53-dependent apoptosis. Mol Cell BioL 1994;14:2556.
60. [60] Imamura J, Miyoshi I, Koeffler H. p53 in hematologic malignancies. Blood 1994;84:2412.
61. [61] Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood 1994;84:2391.